Abstracts tagged "Biologicals"

Abstract Number: 1773 • ACR Convergence 2021
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials
Joris Diels¹, Pushpike Thilakarathne², Agata Schubert³, Fareen Hassan⁴, Steven Peterson⁵ and Wim Noël¹, ¹Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ²JanssenCilag Ltd, HEMAR Department, Beerse, Belgium, ³Janssen-Cilag Poland, HEMAR Department, Warsaw, Poland, ⁴Janssen-Cilag Ltd, HEMAR Department, High Wycombe, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ
Background/Purpose: Guselkumab is an anti-interleukin (IL)-23 monoclonal antibody recently approved for the treatment of psoriatic arthritis (PsA). In two large Phase III trials of patients…
Abstract Number: 0226 • ACR Convergence 2021
High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial
Bardur Sigurgeirsson¹, John Browning², Stephen Tyring³, Jacek Szepietowski⁴, Raquel Rivera‐Díaz⁵, Isaak Effendy⁶, Deborah Keefe⁷, Gerard Bruin⁸, Bertrand Paguet⁹, Rong Fu¹⁰, Isabelle Hampele⁹ and Maximilian Reinhardt⁹, ¹University of Iceland, Reykjavík, Iceland, ²Texas Dermatology and Laser Specialists, Texas, TX, ³Center for Clinical Studies, Texas, ⁴Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland, ⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Departrment of Dermatology and Allergology, University Hospital of Bielefeld, Bielefeld, Germany, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Institutes for Biomedical Research, Basel, Switzerland, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Institutes of for Biomedical Research, Shanghai, China (People's Republic)
Background/Purpose: The MATURE study investigated administration of 300 mg secukinumab (SEC) using a 2 mL autoinjector (AI) device. The objective of this study was to…
Abstract Number: 0845 • ACR Convergence 2021
A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study
Panagiotis Athanassiou¹, Andreas Bounas², Dimitrios Boumpas³, Prodromos Sidiropoulos⁴, Christina Tsalapaki⁵, Alexandros Garyfallos⁶, Eleftheria Grika⁷, Paraskevi Voulgari⁸, Angeliki Kekki⁹, Zafeirios Anagnostopoulos⁹, Georgios Karachalios⁹ and Nikos Antonakopoulos⁹, ¹Department of Rheumatology, St. Paul’s Hospital of Thessaloniki, Thessaloniki, Greece, ²General Clinic of Patras “Olympion”, Rheumatology, Patras, Greece, ³“Attikon” University Hospital, Rheumatology and Clinical Immunology Unit ,4th University Pathology Clinic, Athens, Greece, ⁴Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ⁵General Hospital of Athens “Hippokratio", Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁶General Hospital of Thessaloniki “Ippokratio" , Τhessaloniki, Greece, Thessaloniki, Greece, ⁷Rheumatology Clinic, General Hospital “Evangelismos”, Athens, Greece, ⁸Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ⁹Genesis Pharma SA, Athens, Greece, Athens, Greece
Background/Purpose: SB4 is an etanercept biosimilar that obtained EU regulatory approval in 2016, and became available in Greece in 2018. Due to lack of published…
Abstract Number: 1288 • ACR Convergence 2021
First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard of Care Treatment: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Mia Rodziewicz¹, Sarah Dyball¹, Stephen McDonald¹, Emily Sutton¹, Ben Parker¹, The British Isles Lupus Assessment Group² and Ian N. Bruce¹, ¹University of Manchester, Manchester, United Kingdom, ²Lupus Trust, London
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have an increased risk of infection compared to the general population. We aimed to assess the early risk…
Abstract Number: 1356 • ACR Convergence 2021
Effects of TNF-α versus Secukinumab on Active Ultrasound Confirmed Enthesitis in Psoriatic Arthritis
Ashley Elliott¹, Gary Wright², Adrian Pendleton² and Madeleine Rooney¹, ¹Centre for Experimental Medicine , School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, UK, Belfast, Northern Ireland, United Kingdom, ²Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom
Background/Purpose: Enthesitis is an important aspect of disease in PsA and its clinical assessment has problems in terms of sensitivity and overlap with alternative co-morbid…
Abstract Number: 1655 • ACR Convergence 2021
Severe Respiratory Infections in Rheumatoid Arthritis Patients with Biologic Therapy: Comparative Study Between Vaccinated and Non Vaccinated Patients
Lucia Cristina Dominguez Casas¹, Paz Rodriguez-Cundin², Trinidad Dierssen³, Miguel Ángel gonzalez-Gay⁴ and Ricardo Blanco⁵, ¹Hospital Universtario San Agustin, Oviedo, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³University of Cantabria, Santander, Spain, ⁴Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, Santadner, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of severe infections due to the disease itself, and the immunosuppressive treatment. Vaccination programs are designed…
Abstract Number: 1782 • ACR Convergence 2021
Disease Activity in Psoriatic Arthritis Patients with Enthesitis Across Different Therapies
Robert Chao¹, George Reed², Joel Kremer³ and Arthur Kavanaugh⁴, ¹Inova Health System, Fairfax, VA, ²University of Massachusetts, Worcester, MA, ³Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Evidence on the treatment of enthesitis, a common feature of psoriatic arthritis (PsA), is limited. This post-hoc, cross-sectional study examined if prevalent treatment choices…
Abstract Number: 0263 • ACR Convergence 2021
Patterns of Medication Switching in Juvenile Idiopathic Arthritis: A Retrospective Analysis of a National Administrative Claims Database
Mei-Sing Ong¹, Sarah Ringold², Melissa Mannion³, Marc Natter⁴, Laura Schanberg⁵ and Yukiko Kimura⁶, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Seattle Children's Hospital, Seattle, WA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston Children's Hospital, Boston, MA, ⁵Duke University Medical Center, Durham, NC, ⁶Hackensack University Medical Center, New York, NY
Background/Purpose: Although the increasing availability of biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has significantly improved outcomes for patients with Juvenile Idiopathic…
Abstract Number: 0921 • ACR Convergence 2021
Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial
Juergen Braun¹, Ricardo Blanco², Helena Marzo-Ortega³, Lianne Gensler⁴, Filip Van den Bosch⁵, Stephen Hall⁶, Hideto Kameda⁷, Denis Poddubnyy⁸, Marleen van de Sande⁹, Désirée van der Heijde¹⁰, Tingting Zhuang¹¹, Anna Stefanska¹², Aimee Readie¹¹, Hanno Richards¹³ and Atul Deodhar¹⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Hospital University Marqués de Valdecilla, IDIVAL, Division of Rheumatology, Santander, Spain, ³NIHR Leeds Biomedical Research Centre and University of Leeds, Leeds, United Kingdom, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁶Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ⁷Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁸Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁹Amsterdam UMC, University of Amsterdam, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹²Novartis Ireland Limited, Dublin, Ireland, Dublin, Ireland, ¹³Novartis Pharma AG, Basel, Switzerland, ¹⁴Oregon Health & Science University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation of the sacroiliac joints (SIJ) and the spine. Secukinumab (SEC) treatment was clinically efficacious and reduced SIJ…
Abstract Number: 1301 • ACR Convergence 2021
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab blocks soluble B cell activating factor (BAFF) and is the only to date approved targeted treatment for systemic lupus erythematosus (SLE). Identification of…
Abstract Number: 1359 • ACR Convergence 2021
Risk of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Yi-Shao Liu¹, Jawad Bilal², Muhammad Ajmal², Syed Arsalan Ahmed Naqvi³, Zaina Shahid⁴, Kaneez Zahra Rubab Khakwani², Farva Gondal⁵, Irbaz Bin Riaz⁶, Sandipan Bhattacharjee¹, Roxanne Bogucka¹ and C. Kent Kwoh⁷, ¹University of Texas at Austin, Austin, TX, ²University of Arizona, Tucson, AZ, ³Dow University of Health Sciences, Karachi, Pakistan, ⁴Lehigh Valley Health Network, Allentown, PA, ⁵University of Arizona College of Medicine, Tucson, AZ, ⁶Mayo Clinic, Phoenix, AZ, ⁷University of Arizona College of Medicine, Tuscon, AZ
Background/Purpose: A variety of biologic and targeted synthetic disease modifying antirheumatic agents have been widely used among patients with psoriatic arthritis (PsA). Due to the…
Abstract Number: 1685 • ACR Convergence 2021
Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – Placebo and Active Controlled Study
Eugen Feist¹, Saeed Fatenejad², Sergey Grishin³, Elena Korneva³, Evgeniy Nasonov⁴, Anna Rowińska-Osuch⁵, Mikhail Samsonov⁶ and Roy Fleischmann⁷, ¹Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ²SFC Medica, LLC, Charlotte, NC, ³R-Pharm, Moscow, Russia, ⁴V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, ⁵MCM Polimedica, Warsaw, Poland, ⁶RPharm, Moscow, Russia, ⁷Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Olokizumab (OKZ) is a humanized monoclonal antibody targeting IL-6 [1]. Here we present the results of a global phase III, head-to-head, randomized placebo (PBO)…
Abstract Number: 1803 • ACR Convergence 2021
Long-term Safety of Guselkumab (TREMFYA®) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years
Proton Rahman¹, Christopher Ritchlin², Philip Mease³, Philip S Helliwell⁴, Wolf-Henning Boehncke⁵, Iain McInnes⁶, May Shawi⁷, Anne Marilise Marrache⁸, Alexa Kollmeier⁹, Xie Xu¹⁰, Jenny Yu¹⁰, Yanli Wang¹⁰, Shihong Sheng¹⁰ and Alice Gottlieb¹¹, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Geneva University Hospitals, Geneva, Switzerland, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Guselkumab (GUS), a targeted IL-23 inhibitor, demonstrated significant improvements in signs and symptoms of psoriatic arthritis (PsA) and a favorable safety profile through week…
Abstract Number: 0432 • ACR Convergence 2021
Anti-IL5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Longitudinal Follow-up Study ≥ 24months
Allyson Egan¹, Pasupathy Sivasothy², Lisa Willcocks², Rachel Jones², Marcos Martinez Del Pero³ and David R.W. Jayne⁴, ¹Vasculitis and Lupus Centre, Cambridge University Hospital, University of Cambridge, London, United Kingdom, ²Vasculitis and Lupus Centre, Department of Medicine, Cambridge University Hospital, Cambridge, United Kingdom, ³Vasculitis and Lupus Centre, Cambridge University Hospital, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 0932 • ACR Convergence 2021
Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay Von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Späthling-Mestekemper⁸, Christoph Kuhn⁹, Fabian Proft¹⁰, Denis Poddubnyy¹¹, Mathias Englbrecht¹² and Wolfgang Vorbrüggen¹³, ¹Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ²Rhein-Maas Klinikum, Wuerselen, Germany, ³Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, ⁴Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁵Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, ⁶rheumapraxis, Osnabrck, Germany, ⁷Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ⁸Rheumapraxis München, München, Germany, ⁹Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, ¹⁰Charité University Medicine Berlin, Berlin, Germany, ¹¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ¹²Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, ¹³Verein zur Förderung der Rheumatologie e.V., Würselen, Germany
Background/Purpose: Increasing immunmodulatory treatment options are available for axial spondyloarthritis. Little is known about sequential treatment in clinical routine.Methods: The pseudonymized RHADAR database (Kleinert, S.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].